Takotsubo Syndrome and Vaccines: A Systematic Review
Authors' conclusion
TTS is a rare but potentially life-threatening complication of vaccination.
Study context
- Population
- Patients with TTS associated with vaccination (case reports/case series up to 26 April 2023)18 reports
- Participants
- 19 patients
- Outcome
- Characteristics of vaccine-induced TTS
Pooled result
As reported in the abstract
- Female
- 68.4%
- Mean age
- 56.6 ± 21.9 years
- TTS after COVID-19 vaccination
- 17
- mRNA vaccine (of COVID-19 cases)
- 14
- TTS after influenza vaccination
- 2
- Median time to symptom onset (IQR 1-4)
- 2 days
- Chest pain
- 68.4%
- Dyspnoea
- 57.9%
- Digestive symptoms
- 31.6%
- Nonspecific symptoms (fatigue, myalgia, diaphoresis, fever)
- 57.9%
- Elevated cardiac troponin (of 16 reported)
- 15 (93.8%)
- Elevated natriuretic peptide (of 9 reported)
- 8 (88.9%)
- ST-segment change
- 47.1%
- T-wave inversion
- 58.8%
- Prolonged corrected QT interval
- 35.3%
- Apical ballooning
- 88.2%
- Discharged with improved symptoms
- 81.3%
- Recovered ventricular wall motion during follow-up
- 9 (56.3%)
- Died
- 2 (12.5%)
Further pooled results
Diagnostic workup
- Transthoracic echocardiography
- 17 (89.5%)
- Angiography
- 16 (84.2%)
- CMR
- 7 (36.8%)
In-hospital treatment
- Beta-blockers
- 44.4%
- ACEi/ARB
- 33.3%
- Diuretics
- 22.2%
Original publication
Takotsubo Syndrome and Vaccines: A Systematic Review. ESC Heart Fail. Published 12 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →